Lyell Immunopharma, Inc.
LYL273
metastatic colorectal cancer (mCRC)
Countdown
177days
Phase 1 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 1 trial results for LYL273 in metastatic colorectal cancer (mCRC) are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 12h ago
“A second data update including clinical outcomes expected in the second half of 2026.”